

**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

May 14, 2024: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:35 - 6:50**

- **Chief Medical Officer Updates** **6:50 - 6:55**

- **Follow-up Items from Previous Meetings** **6:55 - 7:00**
 - None at this time.

- **RetroDUR/ProDUR** **7:00- 7:00**
 - None at this time.

- **Clinical Update: Drug Reviews** **7:00-7:45**
(Public comment prior to Board action)
 - **Biosimilar Drug Reviews**
 - None at this time.

 - **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Airsupra[®] (albuterol/budesonide)
 - Furoscix[®] (furosemide injection)
 - Iyuzeh[™] (latanoprost)
 - Likmez[™] (metronidazole)
 - Miebo[®] (perfluorohexyloctane)
 - Rykindo[®] (risperidone injection, extended release)
 - Sohonos[™] (palovarotene)
 - Xdemvy[®] (lotilaner)

- **New Managed Therapeutic Drug Classes** **7:45 -7:45**
 - None at this time.

- **Therapeutic Drug Classes – Periodic Review** **7:45 - 8:25**
(Public comment prior to Board action)
 - Alpha-1 Proteinase Inhibitors
 - Anti-parasitics, Topical
 - Atopic Dermatitis

- Bladder Relaxants
 - BPH Agents
 - Colony Stimulating Factors
 - Erythropoiesis Stimulating Agents
 - Idiopathic Pulmonary Fibrosis
 - Immunosuppressants, Oral
 - Movement Disorder Agents
 - Select Contraceptive Products
-
- **Review of Newly Developed/Revised Criteria** **8:25 - 8:25**
(Public comment prior to Board action)
 - None at this time.
-
- **General Announcements** **8:25 – 8:30**
 - Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market
-
- **Adjourn** **8:30pm**